Nonclinical pharmacology and toxicology data review
An independent read of research-stage in vitro and in vivo work: study design, dose-response and EC50/IC50 data, mechanism-of-action evidence, and the figures and tables built from them. I check that each conclusion follows from the data and flag the gaps.
On the record: drug-induced toxicity studies in cell lines, zebrafish and mouse models at Wayne State (2018 to 2022); dose-response studies of the gamma-secretase inhibitor nirogacestat in patient-derived desmoid tumor cell lines at Memorial Sloan Kettering (2023 to 2024).